Critical Review: VivoSim Labs (NASDAQ:VIVS) & Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences (NASDAQ:MRVI) and VivoSim Labs (NASDAQ:VIVS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Volatility and Risk

Maravai LifeSciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Maravai LifeSciences and VivoSim Labs, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1	1	2	1	2.60
VivoSim Labs	1	0	0	0	1.00

Maravai LifeSciences currently has a consensus price target of $7.38, suggesting a potential downside of 1.93%. Given Maravai LifeSciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Maravai LifeSciences is more favorable than VivoSim Labs.

Earnings and Valuation

This table compares Maravai LifeSciences and VivoSim Labs”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74 million	10.51	-$130.77 million	($0.43)	-17.49
VivoSim Labs	$130,000.00	18.07	-$13.84 million	($4.47)	-0.03

VivoSim Labs has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

50.2% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 1.0% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Maravai LifeSciences and VivoSim Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

Summary

Maravai LifeSciences beats VivoSim Labs on 11 of the 15 factors compared between the two stocks.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

About VivoSim Labs

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.